Taipei Exchange - Delayed Quote TWD

Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO)

Compare
70.10 +0.10 (+0.14%)
As of 9:06 AM GMT+8. Market Open.
Loading Chart for 4747.TWO
DELL
  • Previous Close 70.00
  • Open 73.50
  • Bid 69.50 x --
  • Ask 73.00 x --
  • Day's Range 70.10 - 73.50
  • 52 Week Range 61.20 - 92.00
  • Volume 14,000
  • Avg. Volume 85,855
  • Market Cap (intraday) 3.15B
  • Beta (5Y Monthly) -0.39
  • PE Ratio (TTM) 39.60
  • EPS (TTM) 1.77
  • Earnings Date --
  • Forward Dividend & Yield 1.50 (2.05%)
  • Ex-Dividend Date Jun 21, 2024
  • 1y Target Est --

Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials, and products in Taiwan. The company offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamin, anti-inflammatory, cough and cold, pain reliever, etc. It provides its products in the solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. Johnson Chemical Pharmaceutical Works Co., Ltd. was incorporated in 1959 and is based in New Taipei City, Taiwan.

www.jcpjohnson.com.tw

167

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4747.TWO

View More

Performance Overview: 4747.TWO

Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

4747.TWO
14.51%
TSEC CAPITALIZATION WEIGHTED ST
26.27%

1-Year Return

4747.TWO
17.38%
TSEC CAPITALIZATION WEIGHTED ST
30.97%

3-Year Return

4747.TWO
137.33%
TSEC CAPITALIZATION WEIGHTED ST
30.35%

5-Year Return

4747.TWO
137.35%
TSEC CAPITALIZATION WEIGHTED ST
95.57%

Compare To: 4747.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4747.TWO

View More

Valuation Measures

Annual
As of 11/26/2024
  • Market Cap

    3.15B

  • Enterprise Value

    2.24B

  • Trailing P/E

    39.55

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.27

  • Price/Book (mrq)

    1.87

  • Enterprise Value/Revenue

    3.62

  • Enterprise Value/EBITDA

    17.09

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.63%

  • Return on Assets (ttm)

    3.28%

  • Return on Equity (ttm)

    6.06%

  • Revenue (ttm)

    616.34M

  • Net Income Avi to Common (ttm)

    77.82M

  • Diluted EPS (ttm)

    1.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.11B

  • Total Debt/Equity (mrq)

    8.99%

  • Levered Free Cash Flow (ttm)

    66.09M

Research Analysis: 4747.TWO

View More

Company Insights: 4747.TWO

Research Reports: 4747.TWO

View More

People Also Watch